Safety and Efficacy of APD356 in the Treatment of Obesity

Summary

This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity. The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.

Timeline

Start

2004-12

Primary completion

—

Completion

2005-05

Drugs

Indications